Cognitive effects of estradiol after menopause

Neurology

Volumn 87, Issue 7, 2016, Pages 699-708

  Henderson, Victor W ^a   St John, Jan A ^a   Hodis, Howard N ^b   McCleary, Carol A ^a   Stanczyk, Frank Z ^c   Shoupe, Donna ^d   Kono, Naoko ^a   Dustin, Laurie ^e   Allayee, Hooman ^a   Mack, Wendy J ^f  

^a Departments of Health Research and Policy   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Atherosclerosis Research Unit   (United States)

^d Medicine Neurology   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ESTRADIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROGESTERONE; AGENTS USED INTRAVAGINALLY; ESTROGEN; GESTAGEN;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NEUROPSYCHOLOGICAL TEST; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERBAL MEMORY; AGED; DRUG EFFECTS; ESTROGEN THERAPY; FOLLOW UP; MIDDLE AGED; PROCEDURES;

AGED; COGNITION; DOUBLE-BLIND METHOD; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EXECUTIVE FUNCTION; FOLLOW-UP STUDIES; HUMANS; MEMORY, EPISODIC; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE; PROGESTINS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84983087697     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002980     Document Type: Article

References (31)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimers disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984;34:939-944.
2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011;7:263-269.
3. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
4. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status: correlations with standardized psychometric testing. Arch Neurol 1991;48: 725-728.
5. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimers disease spectrum. Brain 2015;138:1370-1381.
6. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age, sex, and APOE e4 effects on memory, brain structure, and betaamyloid across the adult life span. JAMA Neurol 2015;72: 511-519.
7. Knopman DS, Jack CR Jr, Wiste HJ, et al. (18)F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging 2014;35:2096-2106.
8. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
9. Jack CR Jr, Wiste HJ, Weigand SD, et al. Different definitions of neurodegeneration produce similar frequencies of amyloid and neurodegeneration biomarker groups by age among cognitively non-impaired individuals. Brain 2015;138:3747-3759.
10. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18FFDG and PiB PET in cognitive impairment. J Nucl Med 2009;50:878-886.
11. Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR Jr. Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage 2005;26:600-608.
12. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
13. Jack CR Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimers Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765-775.
14. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-Term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012;78:1576-1582.
15. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32:1207-1218.
16. Jack CR Jr, Wiste HJ, Weigand SD, et al. Age-specific population frequencies of cerebral beta-Amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: A cross-sectional study. Lancet Neurol 2014;13:997-1005.
17. Ashburner J. Computational anatomy with the SPM software. Magn Reson Imaging 2009;27:1163-1174.
18. Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. Cereb Cortex 2005;15: 1676-1689.
19. Driscoll I, Davatzikos C, An Y, et al. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009;72:1906-1913.
20. Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. What is normal in normal aging? Effects of aging, amyloid and Alzheimers disease on the cerebral cortex and the hippocampus. Prog Neurobiol 2014;117:20-40.
21. Thambisetty M, Wan J, Carass A, et al. Longitudinal changes in cortical thickness associated with normal aging. Neuroimage 2010;52:1215-1223.
22. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimers disease. Neurology 1997;49:786-794.
23. van de Pol LA, Hensel A, Barkhof F, et al. Hippocampal atrophy in Alzheimer disease: Age matters. Neurology 2006;66:236-238.
24. Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimers disease in relation to ApoE genotype and biomarkers. Brain 2009;132: 1067-1077.
25. Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and brain structure. Neurology 2009;73:1899-1905.
26. Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med 2009;360:2302-2309.
27. Kantarci K, Senjem ML, Lowe VJ, et al. Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol 2010;31: 1247-1253.
28. Murray ME, Graff-Radford NR, Ross OA, et al. Neuropathologically defined subtypes of Alzheimers disease with distinct clinical characteristics: A retrospective study. Lancet Neurol 2011;10:785-796.
29. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimers disease: A case-control study. Lancet Neurol 2012;11:868-877.
30. Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in early-onset Alzheimers disease is not related to amyloid burden. Brain 2010;133: 512-528.
31. Lehmann M, Ghosh PM, Madison C, et al. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. J Neurol Neurosurg Psychiatry 2014;85:266-273.